Christopher J. Tovey - May 5, 2021 Form 3 Insider Report for Jazz Pharmaceuticals plc (JAZZ)

Role
EVP COO & Managing Dir EUR/INT
Signature
By: /s/Adam Guttmann, as attorney in fact For: Christopher J Tovey
Stock symbol
JAZZ
Transactions as of
May 5, 2021
Transactions value $
$0
Form type
3
Date filed
5/7/2021, 04:24 PM
Next filing
Mar 9, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
holding JAZZ Ordinary Shares 25 May 5, 2021 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding JAZZ Non-Qualified Stock Option (right to buy) May 5, 2021 Ordinary Shares 8.06K $0.02 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Option to acquire Jazz Ordinary Shares received upon conversion of options to acquire shares of GW Pharmaceuticals PLC ("GW") pursuant to the GW Transaction Agreement among Jazz Pharmaceuticals UK Holdings Limited, Jazz Pharmaceuticals Public Limited Company and GW dated February 3, 2021 (the "Merger"). The effective date of the Merger was May 5, 2021. Fifty percent of the award will vest and be available for exercise on February 22, 2022 and fifty percent will vest and be available for exercise on February 22, 2023 in accordance with the terms of the Merger.